<DOC>
	<DOC>NCT00458601</DOC>
	<brief_summary>This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy). Study treatment will be given until disease progression and patients will be followed for long-term survival information. Efficacy will be measured by the progression-free survival status at 5.5 months from the date of first dose.</brief_summary>
	<brief_title>Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue. Gross total resection followed by conventional chemoradiation therapy without progression of disease. Presence of diffuse leptomeningeal disease or gliomatosis cerebri. Systemic corticosteroid therapy &gt; 2 mg of dexamethasone or equivalent (as defined by the investigator) per day at study enrollment. Patients who have undergone stereotactic radiosurgery prior to or following surgical resection, or the placement of GliadelÂ® Wafers. Known allergy or hypersensitivity to KLH, GMCSF or yeast derived products, or a history of anaphylactic reactions to shellfish proteins.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>EGFRvIII vaccinetemozolomidecancer vaccineimmunotherapy</keyword>
</DOC>